Elicera Therapeutics AB (SE:ELIC)

:ELIC

ELIC

Elicera Therapeutics AB

RESEARCH TOOLSreports

Want to see SE:ELIC full AI Analyst Report?

Elicera Therapeutics AB (ELIC) Price & Analysis

3 Followers

ELIC Stock Chart & Stats

kr5.35

kr0.03(1.27%)

At close: Mar 06 4:00 PM EST

kr5.35

kr0.03(1.27%)

Day’s Range― - ―

52-Week Rangekr3.06 - kr8.43

Previous CloseN/A

Volume204.65K

Average Volume (3M)134.24K

Market Cap

kr153.37M

Enterprise Valuekr135.51M

Total Cash (Recent Filing)kr24.85M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.04

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares Outstanding48,535,545

10 Day Avg. Volume92,396

30 Day Avg. Volume134,243

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)10.19

Price to Sales (P/S)0.00

P/FCF Ratio-11.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.51

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet (Zero Debt)A zero-debt capital structure materially lowers solvency risk and interest burden, preserving flexibility to raise equity or partner for R&D funding. This structural financial conservatism supports runway management and downside protection during multi-year clinical development.

Platform Focus In Immuno‑OncologyA diversified platform spanning CAR T, oncolytic viruses and an iTANK enhancement tech gives multiple scientific routes to commercialization. This modality breadth reduces single-program dependency and offers durable upside if any platform yields a viable therapeutic or partnership.

High Gross Margins When Revenue ExistedNear full pass-through gross margins imply low cost of goods for existing revenue streams, indicating attractive unit economics if commercial products emerge. Durable margin leverage can translate R&D success into rapid improvement in operating leverage and profitability.

Bears Say

Zero Revenue In 2025 And Volatile Top LineA drop to zero reported revenue eliminates near-term commercial visibility and indicates no self-sustaining sales base. Over the medium term, the company will remain funding-dependent until clinical or commercial milestones create consistent revenue, raising execution and financing risk.

Consistent Negative Cash FlowPersistent negative operating and free cash flow reflects an inability to self-fund R&D and operations. Structurally, this necessitates recurrent equity or partnership financing, increasing dilution risk and making long-term program continuity contingent on successful capital raises or deals.

Shrinking Equity And Negative ROEA materially shrinking equity base and negative returns on equity signal cumulative losses eroding the capital cushion. This weakens resilience to setbacks, narrows strategic options, and elevates the probability that future financing will be dilutive or come with onerous terms.

ELIC FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was kr3.06 and its highest was kr8.43 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is kr153.37M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Aug 27, 2026 which is in 118 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Elicera Therapeutics AB released its earnings results on Apr 28, 2026. The company reported -kr0.104 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.104.

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 48,535,545 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Elicera Therapeutics AB reported an EPS of -kr0.104 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.88%.

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in SE:ELIC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.